Survival rates

Benign brain tumor survival rates

Survival rates for benign brain tumors are based on large groups of people. These rates cannot predict what will happen for each person. A person's outlook depends on the tumor type, location, size and growth rate, whether the tumor can be removed or controlled, and a person's age and overall health.

Survival rates are generally favorable for many benign brain tumors. But survival is only one part of prognosis. A benign brain tumor still can affect vision, hearing, balance, movement, thinking, memory or hormone function depending on where it grows.

The survival rates shown below are based on age groups of 0 to 14, 15 to 39, and 40 and older.

Survival rates in children

For children, five-year relative survival is high for benign brain and other central nervous system tumors. Relative survival compares people with the same type of tumor to people in the general population.

Child age group 5-year relative survival
Ages 0 to 14 97.5%

Survival rates in adults

For adults, five-year relative survival varies by age group. Relative survival compares people with the same type of tumor to people in the general population.

Adult age group 5-year relative survival
Ages 15 to 39 98.3%
Ages 40 and older 90.3%

Survival rates by tumor location

Ten-year survival rates are reported by tumor location for all ages combined. These rates are not specific to adults or children. But these rates can still be useful because survival varies by where the tumor starts.

Tumor location Related tumor type 5-year relative survival 10-year relative survival
Cerebral meninges Meningioma 88.3% 83.6%
Pituitary gland Pituitary adenoma 96.8% 95.2%
Acoustic nerve Acoustic neuroma, also called vestibular schwannoma 99.5% 99.5%
Craniopharyngeal duct Craniopharyngioma 84.8% 77.2%

These are survival rates by tumor location, not by exact tumor diagnosis. The rates are based on primary benign brain and other central nervous system tumors reported in the United States from 2004 to 2021.

Some benign or low-grade brain tumor types are not listed in the table because they do not match one clear tumor-location category. Low-grade gliomas, for example, can start in different areas of the brain. Hemangioblastomas often form in the central nervous system, but the survival data do not provide a clear benign hemangioblastoma location category. For these tumors, prognosis depends on the exact tumor type, location, size and growth rate, whether the tumor can be removed or controlled, and whether it affects important brain functions.

14/08/2026
  1. Price M, et al. CBTRUS statistical report: Primary brain and other central nervous system tumors diagnosed in the United States in 2018-2022. Neuro-Oncology. 2025; doi:10.1093/neuonc/noaf194.
  2. Horbinski C, et al. Central nervous system cancers, version 2.2022: Featured updates to the NCCN Guidelines. Journal of the National Comprehensive Cancer Network. 2023; doi:10.6004/jnccn.2023.0002.
  3. Goldbrunner R, et al. EANO guideline on the diagnosis and management of meningiomas. Neuro-Oncology. 2021; doi:10.1093/neuonc/noab150.
  4. Olson JJ, et al. Congress of Neurological Surgeons systematic review and evidence-based guidelines on the treatment of adults with vestibular schwannomas: Executive summary. Neurosurgery. 2018; doi:10.1093/neuros/nyx586.
  5. Dunn IF, et al. Congress of Neurological Surgeons systematic review and evidence-based guidelines on the role of imaging in the diagnosis and management of patients with vestibular schwannomas. Neurosurgery. 2018; doi:10.1093/neuros/nyx510.
  6. Freda PU, et al. Pituitary incidentaloma: An Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology & Metabolism. 2011; doi:10.1210/jc.2010-1048.
  7. Supbumrung S, et al. Effect of the enhanced recovery protocol in patients with brain tumors undergoing elective craniotomies: A systematic review and meta-analysis. Neurosurgical Focus. 2023; doi:10.3171/2023.9.FOCUS23316.
  8. Strømsnes TA, et al. Growth dynamics of incidental meningiomas: A prospective long-term follow-up study. Neuro-Oncology Practice. 2022; doi:10.1093/nop/npac088.
  9. Gajjar A, et al. Pediatric Central Nervous System Cancers, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology. Journal of the National Comprehensive Cancer Network. 2025; doi:10.6004/jnccn.2025.0012.
  10. Elsevier Point of Care. Clinical Overview: Brain neoplasm, benign and low grade. https://www.clinicalkey.com. Accessed June 29, 2026.
  11. Winn HR, ed. Brain tumors: An overview of current histopathologic and genetic classifications. In: Youmans and Winn Neurological Surgery. 8th ed. Elsevier; 2023. https://www.clinicalkey.com. Accessed June 29, 2026.
  12. Medical review (expert opinion). Mayo Clinic. July 16, 2026.